Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Department of Epidemiology, Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.
Diabetes Metab Res Rev. 2022 Jul;38(5):e3528. doi: 10.1002/dmrr.3528. Epub 2022 Apr 1.
OBJECTIVES: The aim of this study was to assess adrenal gland volume by using magnetic resonance imaging (MRI) and to study its role as an indirect marker of impaired glucose metabolism and hypothalamic-pituitary-adrenal (HPA) axis activation in a population-based cohort. METHODS: Asymptomatic participants were enrolled in a nested case-control study and underwent a 3-T MRI, including T1w-VIBE-Dixon sequences. For the assessment of adrenal gland volume, adrenal glands were manually segmented in a blinded fashion. Impaired glucose metabolism was determined using fasting glucose and oral glucose tolerance test. Cardiometabolic risk factors were also obtained. Inter- and intrareader reliability as well as univariate and multivariate associations were derived. RESULTS: Among 375 subjects included in the analysis (58.5% male, 56.1 ± 9.1 years), 25.3% participants had prediabetes and 13.6% had type 2 diabetes (T2DM). Total adrenal gland volume was 11.2 ± 4.2 ml and differed significantly between impaired glucose metabolism and healthy controls with largest total adrenal gland volume in T2DM (healthy controls: 10.0 ± 3.9 ml, prediabetes: 12.5 ± 3.8 ml, T2DM: 13.9 ± 4.6 ml; p < 0.001). In the multivariate analysis, association of T2DM and increased adrenal gland volume was independent of age, sex, hypertension, triglycerides and body mass index (BMI), but was attenuated in subjects with prediabetes after adjustment for BMI. CONCLUSIONS: T2DM is significantly associated with increased adrenal gland volume by MRI in an asymptomatic cohort, independent of age, sex, dyslipidaemia, hypertension and BMI. Adrenal gland volume may represent an indirect marker of impaired glucose metabolism and HPA axis dysfunction.
目的:本研究旨在通过磁共振成像(MRI)评估肾上腺体积,并研究其在基于人群的队列中作为葡萄糖代谢受损和下丘脑-垂体-肾上腺(HPA)轴激活的间接标志物的作用。
方法:无症状参与者被纳入巢式病例对照研究,并接受了 3-T MRI,包括 T1w-VIBE-Dixon 序列。为了评估肾上腺体积,采用盲法手动分割肾上腺。采用空腹血糖和口服葡萄糖耐量试验来确定葡萄糖代谢受损情况。还获得了心血管代谢危险因素。推导了组内和组间的可靠性以及单变量和多变量关联。
结果:在纳入分析的 375 名受试者中(58.5%为男性,56.1±9.1 岁),25.3%的参与者患有糖尿病前期,13.6%患有 2 型糖尿病(T2DM)。总肾上腺体积为 11.2±4.2ml,在葡萄糖代谢受损和健康对照组之间差异显著,T2DM 组的总肾上腺体积最大(健康对照组:10.0±3.9ml,糖尿病前期:12.5±3.8ml,T2DM:13.9±4.6ml;p<0.001)。在多变量分析中,T2DM 和增加的肾上腺体积的关联独立于年龄、性别、高血压、甘油三酯和体重指数(BMI),但在调整 BMI 后,在糖尿病前期患者中减弱。
结论:在无症状队列中,T2DM 与 MRI 显示的肾上腺体积增加显著相关,与年龄、性别、血脂异常、高血压和 BMI 无关。肾上腺体积可能是葡萄糖代谢受损和 HPA 轴功能障碍的间接标志物。
Diabetes Metab Res Rev. 2022-7
Nutr Metab (Lond). 2024-7-9
Front Endocrinol (Lausanne). 2025-3-14
Nutr Metab (Lond). 2024-7-9
J Clin Endocrinol Metab. 2024-1-18